

Cancer Prevention and Control CIRB Meeting Agenda

September 22, 2022

I. Continuing Review

EAZ171, Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women (Protocol Version Date 02/26/21)

II. Continuing Review

NWU2015-06-02, Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial (Protocol Version Date 12/23/20)

III. Continuing Review

S1912CD, A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (Protocol Version Date 07/06/22)

IV. Continuing Review

URCC-19075, Multi-center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN) (Protocol Version Date 03/25/22)



V. Continuing Review

WF-1801, A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy (Protocol Version Date 12/08/21)

VI. Continuing Review

WF-97415, Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT) (Protocol Version Date 04/08/22)

VII. New Study ReReview

EAQ211, Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma (Protocol Version Date 09/09/22)

VIII. New Study - Initial Review

INT22-09-01, A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer (Protocol Version Date 07/29/22)

IX. New Study - Initial Review

S2010, A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen) (Protocol Version Date 08/05/22)



X. Amendment ReReview

UAZ20-01-01, Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy (Protocol Version Date 09/13/22)

XI. Amendment

A211801, BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation (Protocol Version Date 08/26/22)